Neurocrine Biosciences Reports First Quarter 2023 Financial Results

INGREZZA® (valbenazine) First Quarter Net Product Sales of $410 Million INGREZZA® (valbenazine) 2023 Net Product Sales Guidance Reiterated at $1.67 – $1.77 Billion SAN DIEGO, May 3, 2023 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.